Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias

Livio Pagano, Simona Sica, Stefan Hohaus, Luana Fianchi, Alfonso Piciocchi, Anna Candoni, Gianluca Gaidano, Massimo Breccia, Giorgina Specchia, Enrico Maria Pogliani, Luca Maurillo, Maria Antonietta Aloe-Spiriti, Cristina Mecucci, Elena Rossetti, Giovanna Mansueto, Michela Rondoni, Claudio Fozza, Rosangela Invernizzi, Antonio Spadea, Susanna FenuGabriele Buda, Marco Gobbi

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Therapy-related myeloid neoplasms (t-MN) are a complication of cytotoxic treatment for primary tumors and autoimmune diseases. We report data on 277 t-MN patients, recruited between 1999 and 2013 by the Italian Network on Secondary Leukemias (104 retrospectively and 173 prospectively registered). Median age at t-MN diagnosis was 64 years (range, 21-87). Most frequent primary malignancies (PMs) were lymphoproliferative diseases and breast cancer. One hundred and thirty-three patients had received chemotherapy (CHT), 43 patients radiotherapy (RT), and 101 patients combined CHT/RT for PM. Median time between cytotoxic treatment and t-MN was 5.7 years, with t-MN following RT alone associated with significantly longer latency, compared to CHT or combined CHT/RT (mean, 11.2 vs. 7.1 years, P = 0.0005). The addition of topoisomerase-II inhibitors to alkylating agents was associated with shorter latency compared to alkylating agents alone (median, 6 vs. 8.4 years, P = 0.02). Median survival was 14.6 months from t-MN diagnosis, and was significantly longer in patients treated with allogeneic stem cell transplantation. Significant factors for survival at the multivariable analysis included age, adverse karyotype, and degree of anemia. Our data underline the prognostic importance of karyotype and age in t-MN, similar to de novo acute myeloid leukemia. Treatment approaches should not preclude the use of conventional treatments for younger t-MN patients, including allogeneic stem cell transplantation as potentially curative approach. Am. J. Hematol. 90:E80-E85, 2015. © 2015 Wiley Periodicals, Inc.
Original languageEnglish
Pages (from-to)E80-E80-5
JournalAmerican Journal of Hematology
Volume90
DOIs
Publication statusPublished - 2015

Keywords

  • secondary leukemia

Fingerprint

Dive into the research topics of 'Characteristics and outcome of therapy-related myeloid neoplasms: Report from the Italian network on secondary leukemias'. Together they form a unique fingerprint.

Cite this